Amgen Inc. $AMGN Shares Acquired by VestGen Advisors LLC

Key Points

• VestGen Advisors increased its Amgen stake by 38% in the third quarter, holding 10,314 shares valued at approximately $4.35 million. Institutional investors collectively own 76.5% of the company.
• Analyst sentiment remains mixed, with Amgen carrying a consensus “Hold” rating and an average price target of $389.71, below its reported $460.73 share price.
• Amgen exceeded quarterly earnings and revenue expectations, reporting $6.29 in EPS and $10.05 billion in revenue. The company also declared a quarterly dividend of $2.52 per share, equivalent to a 2.2% annual yield.

VestGen Advisors LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 38.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,314 shares of the medical research company's stock after purchasing an additional 2,841 shares during the period. VestGen Advisors LLC's holdings in Amgen were worth $4,347,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. BlackRock Inc. grew its position in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock valued at $17,874,974,000 after buying an additional 2,261,544 shares during the last quarter. State Street Corp lifted its position in Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Amgen by 12.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company's stock worth $1,952,156,000 after purchasing an additional 605,928 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Amgen during the second quarter valued at approximately $1,831,903,000. Finally, Amundi lifted its position in shares of Amgen by 15.2% in the second quarter. Amundi now owns 3,890,189 shares of the medical research company's stock worth $1,408,715,000 after buying an additional 512,883 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research analyst reports. Cantor Fitzgerald raised their price target on Amgen from $400.00 to $440.00 and gave the stock a "neutral" rating in a research report on Monday, October 5th. Bank of America increased their target price on shares of Amgen from $312.00 to $317.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 5th. Jefferies Financial Group reiterated a "hold" rating and set a $410.00 price objective on shares of Amgen in a research report on Wednesday, September 23rd. Truist Financial raised their price target on Amgen from $362.00 to $380.00 and gave the stock a "hold" rating in a research report on Wednesday, October 7th. Finally, Piper Sandler lifted their target price on Amgen from $427.00 to $457.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average price target of $389.71.

Amgen Stock Performance

NASDAQ AMGN opened at $460.73 on Friday. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $468.27. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The business's 50-day simple moving average is $419.32 and its 200-day simple moving average is $374.09. The firm has a market capitalization of $249.08 billion, a P/E ratio of 20.20, a P/E/G ratio of 3.31 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business's quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts predict that Amgen Inc. will post 22.96 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen's payout ratio is 62.65%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst support: RBC Capital reaffirmed its Buy rating, while Goldman Sachs and TD Cowen also maintained Buy recommendations. The continued bullish view provides support ahead of earnings. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Rare-disease pipeline progress: Amgen reported Phase 3 data for dazodalibep in Sjögren’s disease, additional long-term UPLIZNA data in IgG4-related disease and other autoimmune conditions, and a diagnostic collaboration aimed at earlier rare-disease detection. The updates reinforce the company’s effort to expand growth beyond its established products. Rare Disease Updates
• Positive Sentiment: Dividend income: Amgen declared a quarterly dividend of $2.52 per share, or $10.08 annualized, payable December 11 to shareholders of record November 20. The dividend supports the stock’s income appeal. Amgen Fourth-Quarter Dividend
• Neutral Sentiment: Earnings catalyst: Amgen will report third-quarter 2026 results after the market close on November 3, followed by a conference call. Analysts are focused on whether strong sales of products such as Repatha and TEZSPIRE can offset rising expenses, pricing pressure and biosimilar competition. Amgen Third-Quarter Results Announcement
• Negative Sentiment: Profitability concerns: Management has warned that spending will increase, while MariTide trials could consume substantial cash. Investors are assessing whether higher research and development costs and a CFO transition could pressure margins. Amgen Expense and Profit Outlook

Insider Transactions at Amgen

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president owned 6,404 shares of the company's stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 6,222 shares of company stock valued at $2,540,926. Insiders own 0.85% of the company's stock.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.